Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Avadel Pharmaceuticals PLC
Additional Paid In Capital
Avadel Pharmaceuticals PLC
Additional Paid In Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Additional Paid In Capital
$910.4m
|
CAGR 3-Years
17%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Additional Paid In Capital
$4.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Additional Paid In Capital
$431.1m
|
CAGR 3-Years
14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Additional Paid In Capital
€243.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's Additional Paid In Capital?
Additional Paid In Capital
910.4m
USD
Based on the financial report for Sep 30, 2025, Avadel Pharmaceuticals PLC's Additional Paid In Capital amounts to 910.4m USD.
What is Avadel Pharmaceuticals PLC's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
10%
Over the last year, the Additional Paid In Capital growth was 3%. The average annual Additional Paid In Capital growth rates for Avadel Pharmaceuticals PLC have been 17% over the past three years , 10% over the past five years , and 10% over the past ten years .
